Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00048295 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | PHASE3 | COMPLETED | 150 | — | — | May 1, 2002 | - | Aug 15, 2022 | 15 | Belgium, Czechia +4 |
| NCT00048113 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | PHASE3 | COMPLETED | 150 | — | — | Jan 10, 2001 | Apr 27, 2002 | Dec 5, 2022 | 30 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| Alicaforsen | DRUG | - |
Inclusion Criteria 1. Age \>/= 12 years 2. Weight \>/= 36 kg 3. CDAI score of 220 - 400 4. Documentation of Crohn's disease activity by endoscopy, biopsy or imaging in the last 2 years 5. No TNF-α inhibitor treatment for three months prior to first study drug infusion Exclusion Criteria 1. Known ...